Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib (BMN 673) in Advanced Solid Tumors with BRCA Mutations
NCT01989546Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in ovarian cancer, breast cancer, primary peritoneal cancer (PPC), prostate cancer (PCa), pancreatic cancer (PC), sponsored by National Cancer Institute. Started Feb 2014; status: completed.
02
Drugs
talazoparib
03
Conditions
ovarian cancerbreast cancerprimary peritoneal cancer (PPC)prostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01989546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989546.